Gen-Probe and Life Technologies to Co-Distribute SeCore HLA Sequence-Based Typing Products
Gen-Probe Incorporated (NASDAQ: GPRO) and Life Technologies Corporation (NASDAQ: LIFE) today announced they have signed a distribution agreement for SeCore® HLA Sequence-Based Typing (SBT) kits for use with Life Technologies' 3500 Dx Genetic Analyzer.
Under the terms of the agreement, Gen-Probe's LIFECODES unit will have co-exclusive rights to sell SeCore SBT products into the transplant market alongside Life Technologies' dedicated HLA sales force in the United States. LIFECODES will initiate sales of the SeCore HLA SBT line this month. Financial terms of the agreement were not disclosed.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.